⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL451367 | 0.64 | — | — | |
| SCHEMBL21996 | 0.60 | — | — | |
| SCHEMBL454471 | 0.58 | — | — | |
| SCHEMBL3810363 | 0.58 | CYP2A6 (0.31) | — | |
| SCHEMBL130352 | 0.57 | CYP2A6 (0.33) | — | |
| SCHEMBL3807413 | 0.57 | — | — | |
| SCHEMBL3815388 | 0.57 | CYP2A6 (0.33) | — | |
| SCHEMBL21412173 | 0.56 | — | — | |
| SCHEMBL12005 | 0.56 | — | — | |
| SCHEMBL453892 | 0.56 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 251 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016201052-A1 | BRIDGED BICYCLIC KALLIKREIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2016-12-15 | — | — | WO | claimed |
| US-20160362427-A1 | BRIDGED BICYCLIC KALLIKREIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2016-12-15 | — | — | US | claimed |
| EP-2188282-B1 | 1,2-DIAMIDO-ETHYLENE DERIVATIVES AS OREXIN ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-01-23 | — | — | EP | claimed |
| US-20110263662-A1 | 1,2-DIAMIDO-ETHYLENE DERIVATIVES AS OREXIN ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-10-27 | — | — | US | claimed |
| EP-2351737-A1 | 3-Amino-1-arylpropyl indoles and aza-substituted indoles | F. Hoffmann-La Roche AG (CH) | 2011-08-03 | — | — | EP | claimed |
| EP-2236135-A1 | STABLE PHARMACEUTICAL COMPOSITION | Asahi Kasei Pharma Corporation (JP) | 2010-10-06 | — | — | EP | claimed |
| EP-2188282-A2 | 1,2-DIAMIDO-ETHYLENE DERIVATIVES AS OREXIN ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2010-05-26 | — | — | EP | claimed |
| US-20100048893-A1 | Substituted arylalkanoic acid derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-02-25 | — | — | US | claimed |
| US-20100041725-A1 | STABLE PHARMACEUTICAL COMPOSITION | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-02-18 | — | — | US | claimed |
| EP-2006271-A9 | SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2009-07-29 | — | — | EP | claimed |
| US-20070123527-A1 | 3-Amino-1-arylpropyl indoles and aza-substituted indoles and uses thereof | ROCHE PALO ALTO LLC | 2007-05-31 | — | — | US | claimed |
| EP-1660427-A4 | SUBSTITUTED ARYLALKANOIC ACID DERIVATIVE AND USE THEREOF | ASAHI KASEI PHARMA CORP (JP) | 2006-12-20 | — | — | EP | claimed |
| WO-2006070192-A1 | THIAZOLE AND ISOTHIAZOLE DERIVATIVES THAT MODULATE THE ACIVITY OF CDK, GSK AND AURORA KYNASES | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-06 | — | — | WO | claimed |
| EP-1660427-A1 | SUBSTITUTED ARYLALKANOIC ACID DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2006-05-31 | — | — | EP | claimed |
| WO-2005016862-A1 | SUBSTITUTED ARYLALKANOIC ACID DERIVATIVE AND USE THEREOF | ASAHI KASEI PHARMA CORPORATION (JP) | 2005-02-24 | — | — | WO | claimed |
| US-6214829-B1 | NERVOUS SYSTEM, PSYCHOLOGICAL DISORDERS | DUPHAR INTERNATIONAL RESEARCH B.V. (NL) | 2001-04-10 | — | — | US | claimed |
| EP-0900792-A1 | Piperazine and piperidine derivatives as 5-HT1 receptor agonists | DUPHAR INTERNATIONAL RESEARCH B.V (NL) | 1999-03-10 | — | — | EP | claimed |
| EP-0822187-A1 | PYRAZOLE DERIVATIVES AND HERBICIDES | NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) | 1998-02-04 | — | — | EP | claimed |
| EP-0511826-B1 | Phosphosulfonate herbicides | ROHM & HAAS (US) | 1997-07-16 | — | — | EP | claimed |
| EP-0511826-A2 | Phosphosulfonate herbicides | ROHM AND HAAS COMPANY (US) | 1992-11-04 | — | — | EP | claimed |